Key Event: U.S. FDA Approval

Biocon Limited announced that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta® (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells.

Strategic Context and Commentary

Shreehas Tambe, CEO & Managing Director of Biocon Limited, stated that this approval marks a significant milestone in expanding access to high-quality biosimilars. He noted that PEBRILZO is the company's fifth oncology biosimilar to receive U.S. FDA approval, strengthening its anti-cancer portfolio and advancing its commitment to affordable biologic medicines.

European Regulatory Status

In September, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion recommending the granting of a marketing authorization for Biocon's Pertuzumab biosimilar (420 mg/14 mL concentrate solution for infusion) under the brand name Pebrilzo® for the treatment of HER2-positive breast cancer in Europe.

Global Patent Settlement

Biocon announced a global settlement and license agreement with Genentech. This agreement secures the earliest licensed launch date for PEBRILZO in the United States in Q3 of the calendar year 2028.

Portfolio and Pipeline Impact

PEBRILZO will join Biocon's existing portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). The company's growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab.

Market Context: HER2-Positive Breast Cancer

The release provides context on the disease, stating that HER2-positive breast cancer is a subtype characterized by HER2 protein overexpression. It cites that approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026, with about 20% of those diagnoses being HER2-positive.

Basis of Approval and Product Information

The FDA approval for PEBRILZO was based on a comprehensive package containing structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, confirming it is highly similar to the reference product with no clinically meaningful differences.

The document includes extensive safety information, including Boxed Warnings for:

  • Left Ventricular Dysfunction: PEBRILZO can cause subclinical and clinical cardiac failure. Cardiac function must be evaluated prior to and during treatment.
  • Embryo-fetal Toxicity: Exposure can cause embryo-fetal death and birth defects, necessitating effective contraception.

Other key warnings and precautions detailed include Infusion-Related Reactions, Hypersensitivity Reactions/Anaphylaxis, and lists of the Most Common Adverse Reactions for Metastatic Breast Cancer, Neoadjuvant Treatment, and Adjuvant Treatment.

Financial Impact

Financial impact not quantified in the disclosure. The commercial launch is subject to the anticipated timeline, with the U.S. launch secured for Q3 2028 per the Genentech settlement.

Filing and Compliance